Interaction Between Olanzapine and Pregabalin for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting—A Randomized Factorial Clinical Trial With Simulation
Purpose In low- and middle-income settings where NK1 receptor antagonists are often unaffordable, we evaluated the interaction and efficacy of add-on olanzapine plus pregabalin for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Methods In this single-center 2 × 2 factorial, double-blind, add-on placebo-controlled trial, 104 participants receiving HEC were randomly assigned 1:1:1:1 to olanzapine 5 mg, pregabalin 75 mg, their combination, or placebo once daily for 4 days, with standard ondansetron and dexamethasone. The primary outcome was the olanzapine × pregabalin interaction on the mean 5-day Visual Analog Scale (VAS) nausea score. Secondary outcomes included no nausea, no significant nausea (VAS < 2.5), no vomiting, complete response/control, Functional Living Index–Emesis, and adverse events. Clinical-trial simulation explored the interaction at larger n and identified minimum effective doses. Results No significant olanzapine × pregabalin interaction was detected on mean VAS (coefficient, 0.44 [95% CI, –0.89 to 1.77]; P = .52); effects were consistent with additivity at the trial sample size. Simulation at n ≥ 600 suggested a small antagonistic term, interpreted as hypothesis-generating. The combination arm had the lowest overall 5-day VAS (0.89, standard deviation [SD], 1.07) versus placebo (3.68, SD 2.06; analysis of variance P < .001); secondary outcomes favored the combination and are reported as hypothesis-generating. Emax modeling supports a future dose-reduced regimen of olanzapine 5 mg + pregabalin 50 mg once daily or olanzapine 2.5 mg + pregabalin 75 mg once daily to preserve efficacy while reducing toxicity. Sedation and dizziness were more frequent in the study-drug arms. Conclusion In patients receiving HEC, add-on olanzapine 5 mg + pregabalin 75 mg once daily improved nausea control versus placebo, with effects consistent with additivity. No synergy was demonstrated; the simulation-based antagonism signal warrants confirmation, and a dose-reduced combination is proposed for future evaluation.
Authors
- Dillip Kumar Parida (ORCID: https://orcid.org/0000-0001-6463-3286)
- Milan Padhan (ORCID: https://orcid.org/0009-0003-0292-1882)
- Archana Mishra (ORCID: https://orcid.org/0000-0001-8837-299X)
- Debasish Hota (ORCID: https://orcid.org/0000-0002-7339-1773)
- Mathan Kumar Ramasubbu (ORCID: https://orcid.org/0000-0002-5047-7603)
- Rituparna Maiti (ORCID: https://orcid.org/0000-0003-4063-9178)
- Anand Srinivasan (ORCID: https://orcid.org/0000-0002-0663-0922)
- Saroj Kumar Das Majumdar (ORCID: https://orcid.org/0000-0001-7151-6539)
- Priyanka Mukherjee
Institutions
- All India Institute of Medical Sciences Bhubaneswar (IN)
- All India Institute of Medical Sciences (IN)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1200/op-25-00315
- Primary Topic
- Nausea and vomiting management
- Type
- article
- Field-Weighted Citation Impact
- 0.00